Bain Capital Life Sciences Investors, LLC
Insider CIK 1703031 · MRNS 10% owner · RPID 10% owner · DRNA Director, 10% owner · HTFL 10% owner · ANNX 10% owner · APTX 10% owner · SLDB Director, 10% owner · REPL 10% owner · OLMA 10% owner · SWTX 10% owner · ARQT 10% owner · XLO 10% owner · NAMS 10% owner · KYTX 10% owner · KLRA 10% owner
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| RPID RAPID MICRO BIOSYSTEMS, IN | P Buy deriv | 2026-05-20 | 2026-05-22 | 1,463,000 | — | $0 | 1,463,000 | SEC↗ |
| RPID RAPID MICRO BIOSYSTEMS, IN | P Buy deriv | 2026-05-20 | 2026-05-22 | 1,463,000 | — | $0 | 1,463,000 | SEC↗ |
| RPID RAPID MICRO BIOSYSTEMS, IN | P Buy deriv | 2026-05-20 | 2026-05-22 | 1,463,000 | — | $0 | 1,463,000 | SEC↗ |
| HTFL Heartflow, Inc. | S Sale | 2026-04-30 | 2026-04-30 | 56,224 | $30.05 | $1.69M | 8,448,158 | SEC↗ |
| HTFL Heartflow, Inc. | S Sale | 2026-04-30 | 2026-04-30 | 892,533 | $29.18 | $26.04M | 8,504,382 | SEC↗ |
| HTFL Heartflow, Inc. | S Sale | 2026-04-29 | 2026-04-30 | 797,133 | $29.37 | $23.41M | 9,396,915 | SEC↗ |
| HTFL Heartflow, Inc. | S Sale | 2026-04-28 | 2026-04-30 | 254,110 | $30.51 | $7.75M | 10,194,048 | SEC↗ |
| KLRA Kailera Therapeutics, Inc. | C Conversion deriv | 2026-04-20 | 2026-04-20 | 4,145,768 | — | $0 | 0 | SEC↗ |
| KLRA Kailera Therapeutics, Inc. | C Conversion deriv | 2026-04-20 | 2026-04-20 | 16,875,000 | — | $0 | 0 | SEC↗ |
| KLRA Kailera Therapeutics, Inc. | C Conversion | 2026-04-20 | 2026-04-20 | 4,145,768 | — | $0 | 21,020,768 | SEC↗ |
| KLRA Kailera Therapeutics, Inc. | P Buy | 2026-04-20 | 2026-04-20 | 1,562,500 | $16.00 | $25.00M | 22,583,268 | SEC↗ |
| KLRA Kailera Therapeutics, Inc. | C Conversion | 2026-04-20 | 2026-04-20 | 16,875,000 | — | $0 | 16,875,000 | SEC↗ |
| HTFL Heartflow, Inc. | S Sale | 2026-02-04 | 2026-02-06 | 2,000,000 | $28.05 | $56.10M | 10,448,158 | SEC↗ |
| HTFL Heartflow, Inc. | C Conversion deriv | 2025-08-11 | 2025-08-13 | 35,081,564 | — | $0 | 0 | SEC↗ |
| HTFL Heartflow, Inc. | C Conversion deriv | 2025-08-11 | 2025-08-13 | 0 | — | $0 | 0 | SEC↗ |
| HTFL Heartflow, Inc. | C Conversion | 2025-08-11 | 2025-08-13 | 433,924 | $15.20 | $6.60M | 12,448,158 | SEC↗ |
| HTFL Heartflow, Inc. | C Conversion | 2025-08-11 | 2025-08-13 | 12,014,234 | — | $0 | 12,014,234 | SEC↗ |
| SLDB Solid Biosciences Inc. | P Buy deriv | 2025-02-19 | 2025-02-21 | 6,444,170 | $4.03 | $25.97M | 6,444,170 | SEC↗ |
| SLDB Solid Biosciences Inc. | P Buy | 2025-02-19 | 2025-02-21 | 1,000,000 | $4.03 | $4.03M | 5,034,582 | SEC↗ |
| OLMA Olema Pharmaceuticals, Inc | J Other deriv | 2025-01-10 | 2025-01-13 | 3,500,000 | — | $0 | 3,500,000 | SEC↗ |
| OLMA Olema Pharmaceuticals, Inc | J Other | 2025-01-10 | 2025-01-13 | 3,500,000 | — | $0 | 4,300,000 | SEC↗ |
| OLMA Olema Pharmaceuticals, Inc | P Buy | 2025-01-08 | 2025-01-13 | 300,000 | $5.76 | $1.73M | 7,800,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | P Buy deriv | 2024-12-13 | 2024-12-17 | 1,632,653 | $24.50 | $40.00M | 1,632,653 | SEC↗ |
| KYTX Kyverna Therapeutics, Inc. | C Conversion deriv | 2024-02-12 | 2024-02-14 | 12,351,087 | — | $0 | 0 | SEC↗ |
| KYTX Kyverna Therapeutics, Inc. | P Buy | 2024-02-12 | 2024-02-14 | 450,000 | $22.00 | $9.90M | 3,163,868 | SEC↗ |
| KYTX Kyverna Therapeutics, Inc. | C Conversion | 2024-02-12 | 2024-02-14 | 2,713,868 | — | $0 | 2,713,868 | SEC↗ |
| SLDB Solid Biosciences Inc. | A Award | 2024-01-11 | 2024-01-12 | 904,160 | $5.53 | $5.00M | 4,034,582 | SEC↗ |
| ANNX Annexon, Inc. | P Buy | 2023-05-25 | 2023-05-30 | 300,000 | $2.13 | $639.0K | 5,701,926 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | P Buy | 2021-12-10 | 2021-12-10 | 21,812 | $9.56 | $208.5K | 2,802,225 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | P Buy | 2021-12-10 | 2021-12-10 | 3,188 | $10.24 | $32.6K | 2,805,413 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | P Buy | 2021-12-09 | 2021-12-10 | 4,011 | $9.84 | $39.5K | 2,780,413 | SEC↗ |
| XLO Xilio Therapeutics, Inc. | P Buy | 2021-12-08 | 2021-12-10 | 13,458 | $9.62 | $129.5K | 2,776,402 | SEC↗ |
| SWTX SpringWorks Therapeutics, | S Sale | 2021-08-10 | 2021-08-12 | 1,000,000 | $70.25 | $70.25M | 4,831,307 | SEC↗ |
| RPID RAPID MICRO BIOSYSTEMS, IN | C Conversion deriv | 2021-07-19 | 2021-07-21 | 35,000,001 | — | $0 | 0 | SEC↗ |
| RPID RAPID MICRO BIOSYSTEMS, IN | C Conversion deriv | 2021-07-19 | 2021-07-21 | 6,672,819 | — | $0 | 0 | SEC↗ |
| RPID RAPID MICRO BIOSYSTEMS, IN | C Conversion | 2021-07-19 | 2021-07-21 | 6,999,998 | — | $0 | 6,999,998 | SEC↗ |
| RPID RAPID MICRO BIOSYSTEMS, IN | P Buy | 2021-07-19 | 2021-07-21 | 100,000 | $20.00 | $2.00M | 8,434,560 | SEC↗ |
| RPID RAPID MICRO BIOSYSTEMS, IN | C Conversion | 2021-07-19 | 2021-07-21 | 1,334,562 | — | $0 | 8,334,560 | SEC↗ |
| SWTX SpringWorks Therapeutics, | S Sale | 2021-03-09 | 2021-03-11 | 1,450,000 | $71.50 | $103.67M | 5,831,307 | SEC↗ |
| APTX Aptinyx Inc. | P Buy | 2020-10-26 | 2020-10-27 | 3,333,333 | $3.00 | $10.00M | 8,891,758 | SEC↗ |
| ANNX Annexon, Inc. | C Conversion deriv | 2020-07-28 | 2020-07-28 | 22,222,221 | — | $0 | 0 | SEC↗ |
| ANNX Annexon, Inc. | C Conversion deriv | 2020-07-28 | 2020-07-28 | 2,812,543 | — | $0 | 0 | SEC↗ |
| ANNX Annexon, Inc. | P Buy | 2020-07-28 | 2020-07-28 | 400,000 | $17.00 | $6.80M | 3,241,628 | SEC↗ |
| ANNX Annexon, Inc. | C Conversion | 2020-07-28 | 2020-07-28 | 319,243 | — | $0 | 2,841,628 | SEC↗ |
| ANNX Annexon, Inc. | C Conversion | 2020-07-28 | 2020-07-28 | 2,522,385 | — | $0 | 2,522,385 | SEC↗ |
| ARQT Arcutis Biotherapeutics, I | C Conversion deriv | 2020-02-04 | 2020-02-06 | 2,825,602 | — | $0 | 0 | SEC↗ |
| ARQT Arcutis Biotherapeutics, I | C Conversion deriv | 2020-02-04 | 2020-02-06 | 859,573 | — | $0 | 0 | SEC↗ |
| ARQT Arcutis Biotherapeutics, I | C Conversion | 2020-02-04 | 2020-02-06 | 2,825,602 | — | $0 | 2,825,602 | SEC↗ |
| ARQT Arcutis Biotherapeutics, I | P Buy | 2020-02-04 | 2020-02-06 | 294,117 | $17.00 | $5.00M | 3,979,292 | SEC↗ |
| ARQT Arcutis Biotherapeutics, I | C Conversion | 2020-02-04 | 2020-02-06 | 859,573 | — | $0 | 3,685,175 | SEC↗ |
| DRNA Dicerna Pharmaceuticals In | S Sale | 2019-11-19 | 2019-11-21 | 1,750,000 | $22.03 | $38.55M | 5,580,237 | SEC↗ |
| SWTX SpringWorks Therapeutics, | C Conversion deriv | 2019-09-17 | 2019-09-19 | 1,053,204 | — | $0 | 0 | SEC↗ |
| SWTX SpringWorks Therapeutics, | C Conversion deriv | 2019-09-17 | 2019-09-19 | 6,078,103 | — | $0 | 0 | SEC↗ |
| SWTX SpringWorks Therapeutics, | P Buy | 2019-09-17 | 2019-09-19 | 150,000 | $18.00 | $2.70M | 7,281,307 | SEC↗ |
| SWTX SpringWorks Therapeutics, | C Conversion | 2019-09-17 | 2019-09-19 | 6,078,103 | — | $0 | 6,078,103 | SEC↗ |
| SWTX SpringWorks Therapeutics, | C Conversion | 2019-09-17 | 2019-09-19 | 1,053,204 | — | $0 | 7,131,307 | SEC↗ |
| DRNA Dicerna Pharmaceuticals In | S Sale | 2019-05-29 | 2019-05-31 | 1,600,000 | $12.50 | $20.00M | 7,330,237 | SEC↗ |
| REPL Replimune Group, Inc. | C Conversion deriv | 2018-07-24 | 2018-07-26 | 235,146 | — | $0 | 0 | SEC↗ |
| REPL Replimune Group, Inc. | P Buy | 2018-07-24 | 2018-07-26 | 500,000 | $15.00 | $7.50M | 2,838,968 | SEC↗ |
| REPL Replimune Group, Inc. | C Conversion | 2018-07-24 | 2018-07-26 | 2,338,968 | — | $0 | 2,338,968 | SEC↗ |
| MRNS MARINUS PHARMACEUTICALS IN | S Sale | 2017-12-19 | 2017-12-19 | 94,771 | $7.62 | $722.2K | 4,032,682 | SEC↗ |
| MRNS MARINUS PHARMACEUTICALS IN | S Sale | 2017-12-19 | 2017-12-19 | 55,229 | $7.11 | $392.7K | 3,977,453 | SEC↗ |
| DRNA Dicerna Pharmaceuticals In | M Exercise deriv | 2017-12-18 | 2017-12-19 | 250,000 | $3.19 | $797.5K | 0 | SEC↗ |
| DRNA Dicerna Pharmaceuticals In | P Buy | 2017-12-18 | 2017-12-19 | 285,000 | $7.00 | $2.00M | 285,000 | SEC↗ |
| DRNA Dicerna Pharmaceuticals In | M Exercise | 2017-12-18 | 2017-12-19 | 8,454,388 | — | $0 | 8,739,388 | SEC↗ |
| DRNA Dicerna Pharmaceuticals In | A Award | 2017-12-18 | 2017-12-19 | 190,849 | — | $0 | 8,930,237 | SEC↗ |
| MRNS MARINUS PHARMACEUTICALS IN | S Sale | 2017-12-18 | 2017-12-19 | 300,000 | $7.50 | $2.25M | 4,127,453 | SEC↗ |
| MRNS MARINUS PHARMACEUTICALS IN | S Sale | 2017-12-15 | 2017-12-19 | 102,882 | $8.64 | $888.9K | 4,427,453 | SEC↗ |
| MRNS MARINUS PHARMACEUTICALS IN | S Sale | 2017-12-15 | 2017-12-19 | 719,665 | $8.02 | $5.77M | 4,530,335 | SEC↗ |